108 related articles for article (PubMed ID: 19929405)
1. HER2 polymorphisms and breast cancer in Tunisian women.
Kallel I; Kharrat N; Al-fadhly S; Rebai M; Khabir A; Boudawara TS; Rebaï A
Genet Test Mol Biomarkers; 2010 Feb; 14(1):29-35. PubMed ID: 19929405
[TBL] [Abstract][Full Text] [Related]
2. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.
Nelson SE; Gould MN; Hampton JM; Trentham-Dietz A
Breast Cancer Res; 2005; 7(3):R357-64. PubMed ID: 15987431
[TBL] [Abstract][Full Text] [Related]
3. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
[TBL] [Abstract][Full Text] [Related]
4. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients.
Kara N; Karakus N; Ulusoy AN; Ozaslan C; Gungor B; Bagci H
DNA Cell Biol; 2010 Jul; 29(7):387-92. PubMed ID: 20380571
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
6. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
Stanton SE; Ward MM; Christos P; Sanford R; Lam C; Cobham MV; Donovan D; Scheff RJ; Cigler T; Moore A; Vahdat LT; Lane ME; Chuang E
BMC Cancer; 2015 Apr; 15():267. PubMed ID: 25885598
[TBL] [Abstract][Full Text] [Related]
7. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
8. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Xie D; Shu XO; Deng Z; Wen WQ; Creek KE; Dai Q; Gao YT; Jin F; Zheng W
J Natl Cancer Inst; 2000 Mar; 92(5):412-7. PubMed ID: 10699071
[TBL] [Abstract][Full Text] [Related]
9. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
Cresti N; Lee J; Rourke E; Televantou D; Jamieson D; Verrill M; Boddy AV
Eur J Cancer; 2016 Mar; 55():27-37. PubMed ID: 26773371
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
[TBL] [Abstract][Full Text] [Related]
12. The influence of HER2 genotypes as molecular markers on breast cancer outcome.
Mutluhan H; Akbas E; Erdogan NE; Soylemez F; Senli MS; Polat A; Helvaci I; Seyrek E
DNA Cell Biol; 2008 Oct; 27(10):575-9. PubMed ID: 18721072
[TBL] [Abstract][Full Text] [Related]
13. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
Anticancer Res; 2015 Dec; 35(12):6667-70. PubMed ID: 26637882
[TBL] [Abstract][Full Text] [Related]
14. Association between HER2 and IL-6 genes polymorphisms and clinicopathological characteristics of breast cancer: significant role of genetic variability in specific breast cancer subtype.
Bouhniz OE; Zaied S; Naija L; Bettaieb I; Rahal K; Driss M; Kenani A
Clin Exp Med; 2020 Aug; 20(3):427-436. PubMed ID: 32372374
[TBL] [Abstract][Full Text] [Related]
15. HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.
Nguyen Thanh T; Nguyen Tran BS; Hoang Thi AP; Tran Binh T; Ba Nguyen T; Le Minh T; Nguyen Vu QH; Dang Cong T
Asian Pac J Cancer Prev; 2021 Jan; 22(1):11-18. PubMed ID: 33507673
[TBL] [Abstract][Full Text] [Related]
16. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
Puputti M; Sihto H; Isola J; Butzow R; Joensuu H; Nupponen NN
Cancer Genet Cytogenet; 2006 May; 167(1):32-8. PubMed ID: 16682283
[TBL] [Abstract][Full Text] [Related]
17. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis.
Tao W; Wang C; Han R; Jiang H
Breast Cancer Res Treat; 2009 Mar; 114(2):371-6. PubMed ID: 18438707
[TBL] [Abstract][Full Text] [Related]
18. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
[TBL] [Abstract][Full Text] [Related]
19. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
20. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.
Muendlein A; Hubalek M; Geller-Rhomberg S; Gasser K; Winder T; Drexel H; Decker T; Mueller-Holzner E; Chamson M; Marth C; Lang AH
Eur J Cancer; 2014 Aug; 50(12):2134-41. PubMed ID: 24910416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
